- Home
- CNF vs MIST Comparison
CNF vs MIST Comparison
Compare CNF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | MIST |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.5M | 176.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNF | MIST |
|---|---|---|
| Price | $6.00 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 6.7K | ★ 9.9M |
| Earning Date | 08-28-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,241,013.00 | N/A |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.36 | $0.63 |
| 52 Week High | $13.90 | $3.06 |
Technical Indicators
Market Signals| Indicator | CNF | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 43.69 |
| Support Level | $6.00 | $1.98 |
| Resistance Level | $6.49 | $2.10 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 13.92 | 22.89 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).